Addiction Research

According to the World Health Organization (WHO), addiction is 'a chronic disease of the central nervous system that is characterized by a loss of control over impulsive behavior that leads to compulsive drug seeking and taking, and to relapses even after months of abstinence'. Addiction is a complex neuroadaptive process, where drugs of abuse alter cellular and molecular aspects of neural function. The brain circuits mediating the various behavioral effects of these drugs are rendered more, or less, responsive to those effects.

Addiction Research Products Targets

Products for Addiction Research - Page 44

  1. Cat.No. Product Name Information/Activity
  2. BCC1939 SDZ 220-581 SDZ 220-581 is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7. SDZ 220-581 chemical structure
  3. BCC6730 Synthalin sulfate 182285-12-7 Synthalin sulfate chemical structure
  4. BCC6122 TCN 201 852918-02-6 TCN 201 chemical structure
  5. BCC6123 TCN 213 556803-08-8 TCN 213 chemical structure
  6. BCC6111 TCN 237 dihydrochloride NMDA-IN-1 is a potent and NR2B-selective NMDA antagonist with Ki of 0.85 nM; NR2B Ca2+ influx IC50 is 9.7 nM; no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor. TCN 237 dihydrochloride chemical structure
  7. BCC7482 TCS 46b 302799-86-6 TCS 46b chemical structure
  8. BCC6984 CCMQ 132623-44-0 CCMQ chemical structure
  9. BCC7862 CIQ CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit. CIQ chemical structure
  10. BCC2946 H-Gly-OH Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. H-Gly-OH chemical structure
  11. BCC5888 MNI-caged-NMDA 1227675-52-6 MNI-caged-NMDA chemical structure

Items 431 to 440 of 509 total